Beneficial effects of testosterone undecanoate on the lipoprotein profiles in healthy elderly men. A placebo controlled study

Japanese Heart Journal

Volumn 38, Issue 1, 1997, Pages 73-82

  Uyanik, Bekir Sami ^a   Ari, Zeki ^a   Gümüs, Bilali ^a   Ramazan Yigitoglu M ^a   Arslan, Taciser ^a  

^a CELAL BAYAR UNIVERSITY   (Turkey)

Author keywords

Elderly men; Lipoprotein; Testosterone undecanoate

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; ESTRADIOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TESTOSTERONE; TESTOSTERONE UNDECANOATE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY RISK; HEARTBURN; HUMAN; HUMAN EXPERIMENT; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEXUAL FUNCTION; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0030899133     PISSN: 00214868     EISSN: None     Source Type: Journal    
DOI: 10.1536/ihj.38.73     Document Type: Article

References (38)

1. McKinley JB. Is there an epidemiological basis for a male climacteric syndrome? The Massachusetts male aging study. Menopause: Evaluation, and Health Concerns: 1989; 163-92.
2. Kupperman HS. Treating menopausal women and climacteric men. Medical World News 1974; 15: 32-41.
3. Schonfelder H, Schirren C. Therapy of male fertility disorders and of climacterium virile: effect of a combined chorio-gonadotropin-testosterone treatment. Fortschr Med 1973; 28: 1123-8.
4. Schlegel WS. Climacteric period in men and its therapy. Med Clin 1974; 69: 1037-9.
5. Marin P, Oden B, Björrntorp P. Assimilation and mobilization of triglycerides in subcutaneous abdominal and femoral adipose tissue in vivo in men: effects of androgens. J Clin Endocrinol Metab 1995; 80: 239-43.
6. Godsland IF, Wynn V, Crook D, Miller NE. Sex, plasma lipoproteins, and atherosclerosis: prevailing assumptions and outstanding questions. Am Heart J 1987; 114: 1467-503.
7. Grundy SM. Role of low-density lipoproteins in atherogenesis and development of coronary heart disease. Clin Chem 1995; 41/1: 135-46.
8. Zilversmit DB, Atherogenic nature of triglycerides, postprandial lipidemía, and triglyceride-rich remnant lipoproteins. Clin Chem 1995; 41: 153-8.
9. McGill HC Jr, McMahan CA, Kruski AW, Mott GE. Relationship of lipoprotein cholesterol concentrations of experimental atherosclerosis in baboons. Atherosclerosis 1981; 1: 3-12.
10. Jones DB, Higgins B, Billet JS, et al. The effect of testosterone replacement on plasma lipids and apolipoproteins. Eur J Clin Invest 1989; 19: 438-41.
11. Saizhu W, Ninzhi W. Therapeutic effect of andriol on serum lipids and apolipoproteins in elderly male coronary heart disease patients. Chin Med Sci 1992; 7: 137-41.
12. Asscheman H, Gooren LJG, Megens JAJ, Nauta J, Kloosterboer HJ, Eikelboom F. Serum testosterone level is the major determinant of the male-female differences in serum levels of high-density lipoprotein (HDL) cholesterol and HDL2 cholesterol. Metabolism 1994; 43: 935-9.
13. Vermeulen A. Clinical review 24: androgens in the aging male. J Clin Endocrinol Metab 1991; 73: 221-4.
14. Deslypere JP, Vermeulen A. Aging and tissue androgens. J Clin Endocrinol Metab 1981; 53: 430-4.
15. Davidson JM, Chen JJ, Crapo L, Gray GD, Greenleaf WJ, Catania JA. Hormonal changes and sexual function in aging men, J Clin Endocrinol Metab 1983; 57: 71-7.
16. Read GF, Harper ME, Peeling WB, Griffiths K. Changes in male salivary testosterone concentration with age. Int J Androl 1987; 4: 623-7.
17. Nankin HR, Calkins JH. Decreased bioavailable testosterone in aging normal and impotent men. J Clin Endocrinol Metab 1986; 63: 1418-20.
18. Gray A, Feldman HA, McKinley JB, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts male aging study. J Clin Endocrine Metal 1991; 73: 1016-25.
19. Mitchell R, Hollis S, Claire R, Robertson WR. Age related changes in the pituitary-testicular axis in normal men; lower serum testosterone results from decreased bioactive LH drive. Clin Endocrinol 1995; 42: 501-7.
20. Ongphiphadhanakul B, Rajatanavin R, Chailurkit L, et al. Serum testosterone and its relation to bone mineral density and body composition in normal males. Clin Endocrinol 1995; 43: 727-33.
21. Painter PC, Cope JY, Smith JL. Reference Intervals. In: Burtis CA, Ashwood ER, editors. Tietze Textbook of Clinical Chemistry. Philadelphia: Saunders, 1994: 2175-218.
22. Matsumoto AM. The testis. In: Wyngaarden JB, Smith LH, editors. Cecil Textbook of Medicine, 18th ed. Philadelphia, Saunders, 1988: 1404-21.
23. Bremner WJ, Vitiello MV, Prinz PN. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrine Melab 1983; 56: 1278-82.
24. American Heart Association. The cholesterol facts; a summary of the evidence relating dietary fats, serum cholesterol and coronary heart disease. Circulation 1990; 81: 1721-33.
25. Gordon DJ, Knoke J, Probstfield JL, Superko R, Tyroler HA. High-density lipoprotein cholesterol and coronary heart disease in hypercholestcrolemic men: The Lipid Research Clinics coronary primary prevention trial. Circulation 1986; 74: 1217-25.
26. Corti MC, Guralnik JM, Salive ME, et al. HDL cholesterol predicts coronary heart disease in older persons. JAMA 1995; 274: 539-44.
27. Kannel WB, Wilson PWF. Efficacy of lipid profiles in prediction of coronary heart disease. Am Heart J 1992; 124: 768-74.
28. Stampfer MJ, Sacks FM, Salvine S, Willett WC, Hennekens CH. A prospective study of cholesterol, apoproteins, and the risk of myocardial infarction. N Engl J Med 1991; 325: 373-81.
29. Buring JE, O'Connor GT, Goldhaber. Decreased HDL2 and HDL3 cholesterol, apo A-I and apo A -II, and increased risk of myocardial infarction. Circulation 1992; 85: 22-9.
30. Beigel Y, George J, Leibovici L, Mattityahu A, Sclarovsy S, Blieden L. Coronary risk factors in children of parents with premature coronary artery disease. Acta Pediatric 1993; 82: 162-5.
31. Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrine Metal 1992; 75: 1092-8.
32. Friedl KE, Hannan CJ, Jones RE. High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Metabolism 1990; 39: 69-74.
33. Crist DM, Peake GT, Stackpole PJ. Lipemic and lipoproteinemic effect of natural and synthetic androgens in humans. Clin Exp Pharmacol Physiol 1986; 13: 513-8.
34. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (SM Grundy, Chairman). The second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adults treatment panel II). Circulation 1994; 89: 1329-445.
35. Mayes PA. Lipid transport and storage. In: Murray RK, Granner DK, Mayes PA, Rodwell VW, editors. Harper's Biochemistry. New Jersey: Prentice Hall, 1993: 250-64.
36. Bagatell CJ, Heiman JR, Matsumoto AM, Rivier JE, Bremner WJ. Metabolic and behavioral effects of high-dose exogenous testosterone in healthy men. J Clin Endocrine Metal 1994; 79:561-7.
37. Byerley Lo, Lee WN, Swerdloff RS. Effect of modulating serum testosterone levels in the normal male range on protein, glucose, and lipid metabolism in men: implications for testosterone replacement therapy. Endocr J 1993; 1: 253-62
38. Horst HJ, Holtje WJ, Dennis H. Lymphatic absorption and metabolism of orally administrated testosterone undecanoate. Klin Wochenschr 1976; 54: 875-9.